Transgene SA (TNG.PA)
EUR 0.71
(-1.8%)
EUR 0.71
(-1.8%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -30.01 Million EUR | -18.35% |
| 2022 | -29.9 Million EUR | -27.12% |
| 2021 | -23.52 Million EUR | 1.95% |
| 2020 | -23.99 Million EUR | 5.74% |
| 2019 | -25.45 Million EUR | -445.47% |
| 2018 | 7.36 Million EUR | 126.27% |
| 2017 | -28.04 Million EUR | -23.73% |
| 2016 | -22.66 Million EUR | 36.71% |
| 2015 | -35.8 Million EUR | 23.7% |
| 2014 | -46.93 Million EUR | -13.92% |
| 2013 | -41.19 Million EUR | 2.22% |
| 2012 | -42.13 Million EUR | 6.01% |
| 2011 | -44.82 Million EUR | -29.54% |
| 2010 | -34.6 Million EUR | -26.6% |
| 2009 | -27.33 Million EUR | -24.51% |
| 2008 | -21.95 Million EUR | -194.37% |
| 2007 | -7.45 Million EUR | 66.87% |
| 2006 | -22.51 Million EUR | 0.0% |
| 2004 | -21.67 Million EUR | 1.21% |
| 2003 | -21.93 Million EUR | -7.64% |
| 2002 | -20.37 Million EUR | 16.22% |
| 2001 | -24.32 Million EUR | 1.47% |
| 2000 | -24.68 Million EUR | -13.27% |
| 1999 | -21.79 Million EUR | -57.01% |
| 1998 | -13.88 Million EUR | 5.04% |
| 1997 | -14.61 Million EUR | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | -19.82 Million EUR | 0.0% |
| 2023 Q1 | -7.66 Million EUR | 58.18% |
| 2023 Q4 | -7.33 Million EUR | 0.0% |
| 2023 Q3 | -7.33 Million EUR | 58.45% |
| 2023 Q2 | -17.66 Million EUR | -130.41% |
| 2023 FY | -35.39 Million EUR | -18.35% |
| 2022 Q2 | -18.62 Million EUR | -151.03% |
| 2022 Q1 | -7.41 Million EUR | 43.81% |
| 2022 Q4 | -18.33 Million EUR | -143.43% |
| 2022 FY | -29.9 Million EUR | -27.12% |
| 2022 Q3 | -7.53 Million EUR | 59.55% |
| 2021 Q3 | -5.13 Million EUR | 69.92% |
| 2021 FY | -23.52 Million EUR | 1.95% |
| 2021 Q2 | -17.05 Million EUR | -153.99% |
| 2021 Q4 | -13.2 Million EUR | -157.25% |
| 2021 Q1 | -6.71 Million EUR | 58.12% |
| 2020 Q1 | -5.69 Million EUR | 62.24% |
| 2020 Q4 | -16.03 Million EUR | -147.92% |
| 2020 Q3 | -6.46 Million EUR | 56.51% |
| 2020 Q2 | -14.87 Million EUR | -161.0% |
| 2020 FY | -23.99 Million EUR | 5.74% |
| 2019 Q4 | -15.09 Million EUR | -152.15% |
| 2019 Q3 | -5.98 Million EUR | 64.33% |
| 2019 FY | -25.45 Million EUR | -445.47% |
| 2019 Q1 | -6.71 Million EUR | 10.29% |
| 2019 Q2 | -16.77 Million EUR | -149.92% |
| 2018 FY | 7.36 Million EUR | 126.27% |
| 2018 Q1 | -6.62 Million EUR | -14.54% |
| 2018 Q2 | -6.62 Million EUR | 0.0% |
| 2018 Q4 | -7.48 Million EUR | 0.0% |
| 2018 Q3 | -7.48 Million EUR | -12.95% |
| 2017 Q3 | -5.78 Million EUR | 29.54% |
| 2017 Q1 | -8.2 Million EUR | -43.19% |
| 2017 Q2 | -8.2 Million EUR | 0.0% |
| 2017 FY | -28.04 Million EUR | -23.73% |
| 2017 Q4 | -5.78 Million EUR | 0.0% |
| 2016 Q2 | -5.47 Million EUR | 0.0% |
| 2016 Q1 | -5.47 Million EUR | 21.59% |
| 2016 Q3 | -5.73 Million EUR | -4.66% |
| 2016 FY | -22.66 Million EUR | 36.71% |
| 2016 Q4 | -5.73 Million EUR | 0.0% |
| 2015 Q3 | -6.98 Million EUR | 2.22% |
| 2015 Q2 | -7.14 Million EUR | 0.0% |
| 2015 Q4 | -6.98 Million EUR | 0.0% |
| 2015 FY | -35.8 Million EUR | 23.7% |
| 2015 Q1 | -7.14 Million EUR | 3.84% |
| 2014 FY | -46.93 Million EUR | -13.92% |
| 2014 Q4 | -7.42 Million EUR | 0.0% |
| 2014 Q3 | -7.42 Million EUR | 24.12% |
| 2014 Q2 | -9.79 Million EUR | 0.0% |
| 2014 Q1 | -9.79 Million EUR | -3.31% |
| 2013 Q2 | -11.11 Million EUR | 0.0% |
| 2013 FY | -41.19 Million EUR | 2.22% |
| 2013 Q4 | -9.47 Million EUR | 0.0% |
| 2013 Q1 | -11.11 Million EUR | -7.57% |
| 2013 Q3 | -9.47 Million EUR | 14.73% |
| 2012 Q4 | -10.33 Million EUR | 0.0% |
| 2012 Q3 | -10.33 Million EUR | 0.0% |
| 2012 FY | -42.13 Million EUR | 6.01% |
| 2011 FY | -44.82 Million EUR | -29.54% |
| 2010 FY | -34.6 Million EUR | -26.6% |
| 2009 FY | -27.33 Million EUR | -24.51% |
| 2008 FY | -21.95 Million EUR | -194.37% |
| 2007 FY | -7.45 Million EUR | 66.87% |
| 2006 FY | -22.51 Million EUR | 0.0% |
| 2005 Q2 | -4.92 Million EUR | -585.77% |
| 2005 Q1 | 1.01 Million EUR | 104.32% |
| 2004 Q2 | -5.25 Million EUR | 6.7% |
| 2004 Q1 | -5.62 Million EUR | 17.1% |
| 2004 Q3 | 832.52 Thousand EUR | 115.85% |
| 2004 Q4 | -23.47 Million EUR | -2919.17% |
| 2004 FY | -21.67 Million EUR | 1.21% |
| 2003 FY | -21.93 Million EUR | -7.64% |
| 2003 Q4 | -6.79 Million EUR | -47.81% |
| 2003 Q2 | -5.4 Million EUR | -5.18% |
| 2003 Q3 | -4.59 Million EUR | 15.06% |
| 2003 Q1 | -5.14 Million EUR | -4.92% |
| 2002 Q4 | -4.9 Million EUR | -1.05% |
| 2002 FY | -20.37 Million EUR | 16.22% |
| 2002 Q1 | -5.4 Million EUR | 25.18% |
| 2002 Q2 | -5.32 Million EUR | 1.33% |
| 2002 Q3 | -4.84 Million EUR | 8.98% |
| 2001 Q3 | -5.25 Million EUR | 12.26% |
| 2001 Q1 | -5.83 Million EUR | -12.67% |
| 2001 FY | -24.32 Million EUR | 1.47% |
| 2001 Q4 | -7.21 Million EUR | -37.25% |
| 2001 Q2 | -5.99 Million EUR | -2.64% |
| 2000 Q2 | -4.34 Million EUR | 38.52% |
| 2000 Q4 | -5.18 Million EUR | 35.63% |
| 2000 FY | -24.68 Million EUR | -13.27% |
| 2000 Q3 | -8.05 Million EUR | -85.18% |
| 2000 Q1 | -7.07 Million EUR | 72.01% |
| 1999 Q3 | 751.18 Thousand EUR | -40.41% |
| 1999 FY | -21.79 Million EUR | -57.01% |
| 1999 Q4 | -25.26 Million EUR | -3463.79% |
| 1999 Q1 | 1.48 Million EUR | 105.89% |
| 1999 Q2 | 1.26 Million EUR | -14.94% |
| 1998 FY | -13.88 Million EUR | 5.04% |
| 1998 Q1 | 7.94 Million EUR | 0.0% |
| 1998 Q2 | 646.03 Thousand EUR | -91.87% |
| 1998 Q3 | 427.27 Thousand EUR | -33.86% |
| 1998 Q4 | -25.14 Million EUR | -5986.12% |
| 1997 FY | -14.61 Million EUR | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| ABIONYX Pharma SA | -3.41 Million EUR | -779.601% |
| ABIVAX Société Anonyme | -127.37 Million EUR | 76.438% |
| Adocia SA | -17.62 Million EUR | -70.31% |
| Aelis Farma SA | -6.46 Million EUR | -364.51% |
| Biophytis S.A. | -14.33 Million EUR | -109.391% |
| Advicenne S.A. | -6.45 Million EUR | -364.798% |
| genOway Société anonyme | 2.06 Million EUR | 1553.157% |
| IntegraGen SA | -183.77 Thousand EUR | -16231.284% |
| Medesis Pharma S.A. | -4.22 Million EUR | -609.614% |
| Neovacs S.A. | -6.9 Million EUR | -334.481% |
| NFL Biosciences SA | -4.43 Million EUR | -577.408% |
| Plant Advanced Technologies SA | -778.23 Thousand EUR | -3756.409% |
| Quantum Genomics Société Anonyme | -3.13 Million EUR | -856.633% |
| Sensorion SA | -22.31 Million EUR | -34.519% |
| Theranexus Société Anonyme | -7.64 Million EUR | -292.638% |
| TME Pharma N.V. | -5.62 Million EUR | -433.642% |
| Valbiotis SA | -7.16 Million EUR | -319.162% |
| TheraVet SA | -2.17 Million EUR | -1279.793% |
| Valerio Therapeutics Société anonyme | -20.28 Million EUR | -47.93% |
| argenx SE | -417.15 Million EUR | 92.806% |
| BioSenic S.A. | -7.04 Million EUR | -326.307% |
| Celyad Oncology SA | -8.45 Million EUR | -254.878% |
| DBV Technologies S.A. | -85.24 Million EUR | 64.794% |
| Galapagos NV | -88.26 Million EUR | 65.997% |
| Genfit S.A. | -26.58 Million EUR | -12.912% |
| GeNeuro SA | -14.35 Million EUR | -109.037% |
| Hyloris Pharmaceuticals SA | -15.99 Million EUR | -87.657% |
| Innate Pharma S.A. | -12.66 Million EUR | -136.893% |
| Inventiva S.A. | -102.7 Million EUR | 70.78% |
| MaaT Pharma SA | -19.94 Million EUR | -50.489% |
| MedinCell S.A. | -20.97 Million EUR | -43.071% |
| Nanobiotix S.A. | -26.77 Million EUR | -12.073% |
| Onward Medical N.V. | -35.46 Million EUR | 15.371% |
| Oryzon Genomics S.A. | -4.54 Million EUR | -559.721% |
| OSE Immunotherapeutics SA | -22.98 Million EUR | -30.566% |
| Oxurion NV | -12.11 Million EUR | -147.828% |
| Pharming Group N.V. | -4.87 Million EUR | -515.057% |
| Poxel S.A. | -28.76 Million EUR | -4.339% |
| GenSight Biologics S.A. | -29.69 Million EUR | -1.064% |
| Financière de Tubize SA | -2.14 Million EUR | -1299.83% |
| UCB SA | 604 Million EUR | 104.969% |
| Valneva SE | -82.08 Million EUR | 63.439% |
| Vivoryon Therapeutics N.V. | -28.83 Million EUR | -4.075% |